| 000 | 01869 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250514034304.0 | ||
| 264 | 0 | _c20021217 | |
| 008 | 200212s 0 0 eng d | ||
| 022 | _a0923-7534 | ||
| 024 | 7 |
_a10.1093/annonc/mdf105 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aClark, J I | |
| 245 | 0 | 0 |
_aA multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cApr 2002 |
||
| 300 |
_a606-13 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 |
_aInterleukin-2 _xadministration & dosage |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aKuzel, T M | |
| 700 | 1 | _aLestingi, T M | |
| 700 | 1 | _aFisher, S G | |
| 700 | 1 | _aSorokin, P | |
| 700 | 1 | _aMartone, B | |
| 700 | 1 | _aViola, M | |
| 700 | 1 | _aSosman, J A | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 13 _gno. 4 _gp. 606-13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdf105 _zAvailable from publisher's website |
| 999 |
_c11952758 _d11952758 |
||